The Alliance for Regenerative Medicine Names 32 Member Representatives as New Board of Directors
The Board Will Set the Overall Vision and Direction for the Organization, in Addition to Approving the Annual Budget and Voting on By-Law Amendments
(firmenpresse) - WASHINGTON, DC -- (Marketwired) -- 10/07/15 -- The Alliance for Regenerative Medicine (ARM), the international organization representing the gene therapy, cell therapy and tissue engineering sector, announced it has named its new board of directors, effective immediately.
The board''s primary responsibilities are to set the overall vision and direction for the organization, in addition to approving the annual budget and voting on any necessary by-law amendments.
"Throughout this process, we''ve ensured special considerations were made to reflect the diverse focus areas across our membership," said Morrie Ruffin, managing director of ARM. "We welcome this new board and look forward to leveraging their expertise to propel our growing organization forward and continue to promote the sector."
The new board of directors includes ARM''s current officers: Edward Lanphier, Chairman; Bob Preti, Vice Chairman; Phil Vanek, Secretary; Claudia Zylberberg, Treasurer.
The board will meet a minimum of three times annually, with at least two of those meetings to be held in-person. There is no set term limit for ARM''s board members, however, ARM expects that approximately one-quarter of the board will shift, either during the annual re-election process or owing to voluntary rotation of longest-serving members.
The new board members are as follows:
Zami Aberman, CEO, Pluristem Therapeutics
Martin Andrews, SVP, Rare Disease Head Unit, GSK
Rahul Aras, President and CEO, Juventas
Usman Azam, Global Head Cell & Gene Therapies Unit, Novartis
Doug Doerfler, President & CEO, MaxCyte
Eduardo Bravo, Managing Director and CEO, TiGenix
Flagg Flanagan, CEO, DiscGenics
Christian Homsy, CEO, Celyad
Perry Karsen, CEO, Celgene Cellular Therapeutics
Doug Kerr, Senior Director, Neurology Research & Development, Biogen
Dena Ladd, Executive Director, Missouri Cures
Edward Lanphier, President & CEO, Sangamo BioSciences
Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)
Randy Mills, President & CEO, California Institute for Regenerative Medicine (CIRM)
Matt Patterson, President & CEO, Audentes Therapeutics
Steve Paul, President & CEO, Voyager Therapeutics
Bob Preti, President & Chief Scientific Officer, PCT, a Caladrius Company
Isabelle Riviere, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
Martha Rooke, Director, Stem Cell Bioprocessing Group, EMD Millipore Corporation
Jay Siegel, Chief Biotechnology Officer and Head, Scientific Strategy, Johnson & Johnson
Matthieu Simon, Executive Vice President, Chief Operating Officer, Cellectis
Donna Skerrett, Chief Medical Officer, Mesoblast Limited
David Smith, Head, Cell Therapy Manufacturing, Lonza
Devyn Smith, Head of Strategy for Pharmatherapeutics, Worldwide, Pfizer
Doris Taylor, Director, Regenerative Medicine Research, Texas Heart Institute
Keith Thompson, CEO, UK Cell Therapy Catapult
Gil Van Bokkelen, Chairman and CEO, Athersys
Phil Vanek, General Manager, Cell BioProcessing, GE Healthcare
Alexander Vos, CEO, PharmaCell
Jeff Walsh, COO, bluebird bio
Susan Washer, CEO, AGCT
Claudia Zylberberg, Founder and CEO, Akron Biotechnology, LLC
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit .
Michelle Linn
(774) 696-3803
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.10.2015 - 08:52 Uhr
Sprache: Deutsch
News-ID 1390742
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WASHINGTON, DC
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The Alliance for Regenerative Medicine Names 32 Member Representatives as New Board of Directors
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Alliance for Regenerative Medicine (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
